Ocular Safety and Toxicokinetics of Bevacizumab-bvzr (Zirabev), a Bevacizumab Biosimilar, Administered to Cynomolgus Monkeys by Intravitreal Injection-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Ocular Safety and Toxicokinetics of Bevacizumab-bvzr (Zirabev), a Bevacizumab Biosimilar, Administered to Cynomolgus Monkeys by Intravitreal Injection

Published:2023-04-01 Issue:3 Volume:39 Page:215-224
ISSN:1080-7683
Container-title:Journal of Ocular Pharmacology and Therapeutics
language:en
Short-container-title:Journal of Ocular Pharmacology and Therapeutics

Author:

Peraza Marjorie A.¹,Hurst Susan²,Huang Wenhu³,Buetow Bernard S.³,Lickteig Andrew J.⁴,Lavach J. Dan⁴,Frost Denzil F.⁴,Collins Margaret E.⁴,Sellers Rani S.⁵,Matsumoto Smith Diane³

Affiliation:

1. Drug Safety Research and Development, Pfizer Inc., Cambridge, Massachusetts, USA.

2. Biomedicine Design, Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Groton, Connecticut, USA.

3. Drug Safety Research and Development, Pfizer Inc., San Diego, California, USA.

4. Charles River Laboratories, Inc., Reno, Nevada, USA.

5. Drug Safety Research and Development, Pfizer Inc., Pearl River, New York, USA.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Pharmacology,Ophthalmology

Link

https://www.liebertpub.com/doi/pdf/10.1089/jop.2022.0059

Reference21 articles.

1. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

2. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma

3. Expression of VEGF and its receptors in different brain tumors

4. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP